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Background: Although powerful deﬁbrillation devices are available in clinical practice, risk stratiﬁcation
is important in asymptomatic Brugada syndrome. In this study, vector-projected 187-channel electro-
cardiogram (VP-ECG) was used to calculate the ST-elevation score in Brugada-type ECG and test its
usefulness in risk stratiﬁcation.
Methods and results: VP-ECG was recorded in 108 patients with Brugada-type ECG having ventricular
ﬁbrillation (VF) episodes (7; n¼13/95). The ST morphologies were evaluated in 80/187 precordial
leads. The coved- and saddleback types (4–6 vs. 1–3 points) of ST-elevation scores in 332 recordings were
58757 points, which were calculated using virtual ECG leads. Compared with types 1–3 ECG patterns, the
scores were signiﬁcantly different among the groups (107765, 62745, and 14722, respectively;
po0.01). In patients with VF (), that is, asymptomatic Brugada syndrome, new VF occurrences, family
history, or inducible VF showed a higher score than in those without these occurrences (po0.01).
Conclusion: The ST elevation score in VP-ECG objectively documented the degree of ST elevation in surface
ECG in Brugada-type ECG patterns. The ST-elevation score might be useful for risk stratiﬁcation in patients
with asymptomatic Brugada syndrome.
& 2012 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Brugada syndrome is severe arrhythmia characterized by
speciﬁc ST elevations in precordial leads and sudden ventricular
ﬁbrillation (VF), and the condition may result in sudden cardiac
death [1–5]. By implanting deﬁbrillation devices, also known as
implantable cardioverter-deﬁbrillators (ICDs), sudden death by VF
can be effectively avoided [6–7]; however, the indication of ICD
in asymptomatic Brugada syndrome is controversial [2,4,5]. In
accordance with the consensus report on Brugada syndrome,
asymptomatic Brugada syndrome is deﬁned as the presence
of typical coved-type ST elevations in precordial leads in patients
lacking a history of spontaneous VF [4,5]. ICD therapy guide-
lines [8] emphasize the importance of having only few risk
factors, such as family history of Brugada syndrome, episodes of
syncope, and VF inducibility [3,4,9–11]. However, in clinical
practice, risk stratiﬁcation is often challenging, mainly becausert Rhythm Society. Published by E
: þ81 42 778 8441.
Ishikawa).of the difﬁculties in objectively evaluating ST elevations. In the
consensus report, ST elevations were classiﬁed as types 1–3
on the basis of morphology and degree of ST elevation, but
quantitative evaluation would often be difﬁcult because these
factors may change in different physiological situations. Addi-
tionally, several investigations have shown that patients with
Brugada syndrome and spontaneous VF episodes exhibit ST
elevations only on a speciﬁc area on the chest surface, such as
readings obtained when the ECG leads were placed 1–3 ribs
higher [12,13]. Therefore, systematic evaluation of ST elevation
obtained in multiple leads is necessary for characterizing the ST
elevation.
Vector-projected 187-channel (ch) electrocardiogram system
(VP-ECG or ‘‘DREAM-ECG’’; Fukuda Denshi Co. Ltd., Tokyo) was
designed to create 187-ch virtual surface ECG traces by calculat-
ing from regular 12-lead ECG traces. This technique aids in
analyzing ST-elevation characteristic from ECG traces of any part
of the chest surface. In this study, we used VP-ECG in the analysis
of multiple-lead ECG traces to systematically evaluate ST eleva-
tions in Brugada-type ECG patients. Further, we evaluated the
usefulness of this technique in risk stratiﬁcation.lsevier B.V. All rights reserved.
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2.1. Study population
We examined 108 consecutive patients with Brugada-type
ECGs at our institute. The diagnosis of Brugada-type ECG pattern
from a standard 12-lead ECG recording was based on a consensus
report [4,5]. Further, we included patients with ST elevation types
2–3 in our study population. The mean age was 57713 years, and
102 of the 108 patients were men. The history of all patients was
carefully examined, and we included patients with a history of
syncope and family history of sudden cardiac deaths. The clinical
characteristics of the study patients are summarized in Table 1.
Structural heart disease was ruled out by routine cardiac exam-
inations, including echocardiogram and cardiac catheterization,
during electrophysiologic studies (EPS). The patients were divided
into 2 subgroups, namely, those with and without spontaneous
VF episodes; patients of these subgroups were considered
for secondary and primary prevention of VF during subsequent
analysis.2.2. Analysis of the standard 12-lead ECG
The standard 12-lead ECG was routinely used for recording
during the daytime (9:00 AM–2:00 PM). Additional ECG record-
ings were performed during the night or early morning [15] or by
using chest leads at positions 1–2 ribs higher [12,13], if necessary,
but analyses of these speciﬁc recordings were not included in our
study. Blinded analyses of the ST elevations were performed by
2 investigators. and on the basis of the morphologies and degree
of elevation, the ST elevations were classiﬁed into types 1–3
in accordance with the consensus report on Brugada syndrome
[4,5,16].2.3. Pilsicainide provocation test
A provocation test was performed using pilsicainide, a pure
sodium channel blocker that has shown to cause ST elevations in
patients with Brugada syndrome [5,17–20]. This test was per-
formed to evaluate the risk in patients without a typical coved-
type ST elevation in the standard 12-lead ECG recording. Under
continuous ECG monitoring, pilsicainide at 1 mg/kg body weight
was intravenously administered for 10 min [5]. The test result
was considered positive when a typical coved-type ST elevation of
more than 2 mm appeared [5].Table 1
Clinical characteristics of the patients for primary and secondary preve
Total Prima
Number of patients 108 95
Age (years) 57713 5671
Gender (female:male) 6:102 6:89
Type of ST elevation (Type 1:2:3) 27:46:35 26:41
Family history, n (%) 9 (8.3%) 8 (8.4
Syncope history, n (%) 11 (10.2%) 6 (6.3
VF inducibility in EPS, n (%) 30 (27.8%) 22 (23
Ventricular late potential, n (%) 90 (83.3%) 77 (81
Positive pilsicainide prov., n (%) 58 (71.6%) 49 (71
ICD implantation, n (%) 30 (27.8%) 18 (18
ST elevation score (pts) 5875 6276
Observation (months) 54737 5373
VF recurrence, n (%) 10 (9.3%) 3 (3.2
EPS: electrophysiologic study, Pilsicainide prov.: pilsicainide provocatio
ICD: implantable cardioverter deﬁbrillator, pts: points.
n Statistical signiﬁcance.2.4. Induction of ventricular ﬁbrillation
We performed EPS on the entire study population, including
left ventriculography and coronary angiography to rule out
structural heart disease. The VF induction protocol employed
rapid ventricular stimulation and up to 2 ventricular extrastimuli
with 2 basic cycle lengths at 2 right ventricular sites, namely, the
right ventricular apex and outﬂow tract. The shortening of the
coupling intervals of the extrastimuli was limited to 180 ms to
avoid induction of nonspeciﬁc ventricular arrhythmias [21]. VF
induction was considered positive when a polymorphic ventricu-
lar rhythm lasting over 15 s was induced.
2.5. Recording of vector-projected 187-channel ECG and calculation
of ST elevation score
VP-ECG (Fukuda Denshi, Co. Ltd.) [22,23] recording were
performed during daytime (9:00 AM–2:00 PM), similar to that
followed for standard 12-lead ECG. Each recording was performed
after 15–30 min rest, and the procedure was repeated on 3 differ-
ent days to conﬁrm reproducibility of the procedure. The para-
meters were calculated from these 3 recordings in each case.
Further, daily variations [15], which are time-dependent varia-
tions in ST elevation, were overcome by recording the ECGs at
similar times during the day. However, the daily variation itself
could not be evaluated, because most ECG recordings were
performed in the outpatient clinic of our institute. For calculating
the ST elevation scores, 80/187 virtually projected leads, which
clearly showed the ST elevations, were selected (Fig. 1).
Blinded evaluation of each trace was conducted by 2 investi-
gators to obtain the morphology and degree of the ST elevation.
Coved- and saddleback-shaped morphologies were scored in
accordance with the degree of ST elevation (Fig. 1), and the ﬁnal
ST elevation score was calculated by adding the scores and
numbers of leads in which the ST elevations were observed
[12,13,22,23]. In this study, we set the score for coved-type
ST elevations as 4, 5, or 6 points for a 0.1, 0.2, or Z0.3 mV ST
elevation, respectively; similarly, scores for saddleback-type
ST elevations were 1, 2, or 3 points for a 0.1, 0.2, or Z0.3 mV
ST elevation, respectively. These values were set in accordance
with the relative risk of coved-type vs. saddleback-type ST
elevation described in previous studies [3,11], and also in accor-
dance with results from our previous pilot study on calculating
the ST elevation score for Brugada-type ECG [24]. The ST elevation
score for each patient was calculated as the mean of 3 scores in
3 different VP-ECG recordings.ntion for VF.
ry prevention Secondary prevention p value
13
3 58713 0.5867
0:13 0.4542
:28 1:5:7 0.1404
%) 1 (7.8%) 0.9290
%) 5 (38.5%) 0.0003n
.2%) 8 (61.5%) 0.0038n
.1%) 12 (92.3%) 0.8562
.0%) 9 (75.0%) 0.2313
.9%) 12 (92.3%) o0.0001n
27714 0.0375n
7 63735 0.3386
%) 7 (53.8%) o0.0001n
n test, VF: ventricular ﬁbrillation.
Fig. 1. Calculation of ST elevation scores. The vector-projected 187-channel ECG (VP-ECG) was recorded for each patient, and 80/187 virtually projected leads were
selected for the analysis. In each of the 80 traces, the morphology and degree of ST elevation were evaluated and the ST elevation scores were calculated by adding the
scores and numbers of leads in which ST elevations were observed. See text for details. *SB: saddleback; CV: coved; pts: points.
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Clinical parameters and the ST elevation scores were compared
among different patient subgroups. First, the parameters were
compared among patients for secondary and primary VF prevention,
and subsequently the parameters were compared among patients for
primary prevention, particularly the different types of ECG changes,
namely, types 1–3. Finally, we evaluated the relationship between a
novel ST elevation score and clinical events or standard risk factors to
conﬁrm if ST-elevation score can be used for risk stratiﬁcation. All
studies were performed with the approval of the Clinical Studies and
Ethics Committee of Kitasato University Hospital.
2.7. Statistics
All values are expressed as the mean7standard deviation.
The statistical analyses were performed with one-way analysis ofvariance (ANOVA) or chi-square test. A p value of less than 0.05
was considered signiﬁcant.3. Results
3.1. Comparison of characteristic of patients for primary and
secondary prevention of ventricular ﬁbrillation
Table 1 shows a comparison of clinical characteristics among
the patients for secondary and primary VF prevention. As
reported previously, patients for secondary VF prevention showed
a history of high incidence of syncope and high VF inducibility
during EPS. Therefore, the probability of ICD implantation and VT
recurrences are high among patients for secondary VF prevention.
However, the ST elevation score, which also shows the degree
of ST elevation, was signiﬁcantly low in patients for secondary VF
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mechanism of this difference will be discussed later in the article.
Therefore, in cases where the ST-elevation score is considered,
risk stratiﬁcation should be performed separately for patients
requiring secondary and primary VF prevention.
3.2. Comparison of patient subgroups with different ECG morphologies
Table 2 shows a comparison of subgroups with different types
of ST elevation. Among the 3 subgroups, no signiﬁcant differences
in risk factors and clinical VF events were observed during a
period of 54737 months. In contrast, the ST elevation score was
signiﬁcantly different among the 3 groups, where the scores were
the highest in subgroup 1, intermediate in subgroup 2, and lowest
in subgroup 3.
3.3. Comparison of the ST elevation scores
Fig. 3 shows a comparison of the ST elevation scores between
various subgroups with and without risk factors and/or clinical
events. Among the 95 patients for primary VF prevention, 3 patientsFig. 2. Comparison of ST elevation scores between patients for primary and
secondary prevention. The ST elevation score was signiﬁcantly lower in patients
for secondary prevention of ventricular ﬁbrillation (VF) than in patients for
primary VF prevention, indicating that the coved-type morphology and degree
of ST elevation were more prominent in the primary VF prevention subgroup than
in the secondary VF prevention subgroup. See text for details.
Table 2
Comparison of the patients with different types of ST elevation.
Type 1
Number of patients 27
Age (years) 56713
Gender (female:male) 0:27
VF history, n (%) 1 (3.7%)
Family history, n (%) 4 (14.8%)
Syncope history, n (%) 3 (11.1%)
VF inducibility in EPS, n (%) 12 (44.4%)
Ventricular late potential, n (%) 24 (88.9%)
Positive pilsicainide prov., n (%) 17 (63.0%)
ICD implantation, n (%) 11 (40.7%)
ST elevation score (pts) 107765
Observation (months) 60742
VF recurrence, n (%) 2 (7.4%)
EPS: electrophysiologic study, Pilsicainide prov.: pilsicainide provocatio
ICD: implantable cardioverter deﬁbrillator, pts: points.
n Statistical signiﬁcance.showed VF events during the observation period of 63735 months.
Although only limited number of patients showed VF events, they
exhibited higher ST elevation scores than those without VF events.
Similarly, patients with a family history of VF and/or induced VF
during EPS showed higher ST elevation scores than those without VF
history or VF induction during EPS.
3.4. Three cases of new-onset ventricular ﬁbrillation episodes among
patients for primary prevention
Case 1: A 28-year-old man was referred to our institute
because of Brugada type 2 ECG recordings. He had a history of
syncope and his elder brother had been diagnosed with Brugada
syndrome and had undergone ICD implantation. The patient
showed positive results for the pilsicainide provocation test and
VF could be induced. Although ICD implantation was recom-
mended, the patient rejected this option and was closely followed
up. After 5 years, he suffered a VF episode and was saved by a
bystander who performed cardiopulmonary resuscitation (CPR).
The patient subsequently underwent ICD implantation. Further,
almost all of the 80 leads in the VP-ECG showed some type of ST
elevation, and the ST elevation score was 249 points.
Case 2: A 62-year-old man was referred to our institute
because of Brugada type 1 ECG recording. He had no history of
syncope but one of his relatives had a sudden cardiac death.
Further, positive results were obtained for pilsicainide provoca-
tion test and VF could be induced during EPS. The patient under-
went ICD implantation, but VF occurred 5 years later, and his
ST-elevation score was 208 points.
Case 3: A 70-year-old woman was admitted at our institute
after ICD implantation. Her ECG exhibited a Brugada type-3
pattern ST elevation. She had no history of syncope but her son
had a sudden cardiac death. Positive results were obtained for the
pilsicainide provocation test and VF could be induced during EPS.
The patient had VF 5 years after ICD implantation, and her ST
elevation score was 84 points.4. Discussion
This study evaluated the usefulness of the ST elevation score,
which was calculated from VP-ECG traces, and provided several
interesting ﬁndings. First, the ST-elevation score was signiﬁcantly
higher in patients that require primary VF prevention than in
those that require secondary prevention. Second, the ST-elevation
score quantiﬁed the morphological differences and the degree ofType 2 Type 3 p value
46 35
57712 57714 0.8708
4:42 2:33 0.2931
5 (10.9%) 7 (20.0%) 0.1404
4 (8.7%) 1 (2.9%) 0.3017
4 (8.7%) 4 (11.4%) 0.9066
9 (19.6%) 9 (25.7%) 0.0686
37 (80.4%) 29 (82.9%) 0.6428
25 (54.3%) 16 (45.7%) 0.3991
10 (21.7%) 9 (25.7%) 0.2047
62745 14722 o0.0001n
49737 57731 0.3881
5 (10.9%) 3 (8.6%) 0.8729
n test, VF: ventricular ﬁbrillation.
Fig. 3. Comparison of ST elevation scores between subgroups with and without risk factors and/or clinical events. The ST elevation score was signiﬁcantly higher in
patients with new-onset ventricular ﬁbrillation (VF) than in those without new-onset VF. Further, patients with family history of VF and positive VF induction VF exhibited
higher ST elevation scores than those without VF history and VF induction.
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patterns. Finally, the ST elevation score was high in patients with
new-onset VF episode, risk factors in family history, and inducible
VF during EPS.
4.1. Morphological differences in the ST elevation in patients for
primary and secondary prevention
As shown in various studies, the risk in patients with Brugada-
type ECG patterns with a previous VF episode, i.e, Brugada
syndrome in a narrow sense, is higher than in those without a
previous VF episode [2,4,6,11]. Therefore, one would expect that
patients for secondary VF prevention would exhibit increased
typical ST elevations, especially coved shape, than that by patients
for primary VF prevention. However, we obtained contrasting
results, the reason for which is unclear, but could be explained
by a difference in the screening methods used. The patients for
secondary prevention were usually selected because of VF. It
has been previously shown that typical ST elevations could be
recorded during VF or around the event, but sometimes not on
other days [14,25]. Patients with previous spontaneous VF may
show drastic changes in ST elevations, which may not be detected
by routine daytime ECG recording. In contrast, patients for
primary prevention were usually selected because of ECG changes
during routine ECG examinations. Therefore, patients for primary
prevention may exhibit more prominent ST elevations during
daytime ECG recordings [14,25,26]. By considering these results,
risk stratiﬁcation using ST elevation in surface ECG should be
performed separately in patients for primary and secondary VF
prevention with Brugada-type ECG patterns.
4.2. The role of the ST elevation score in VP-ECG
We present a scoring system of ST elevations by using the
VP-ECG system, which is a unique system that can evaluate multi-
ECG traces on the body surface [22,23,27,28]. The evaluation of ST
elevations from multi-ECG leads might be useful because in somepatients with Brugada syndrome ST elevations are observed only
in selected leads, such as those leads that are placed 1–3 ribs
higher. In this study, we evaluated the degree of ST elevation in
multi-ECG leads by morphology (coved- vs. saddleback type), area
(number of leads), and degree of ST elevation in the ECG traces
recorded by using VP-ECG, and summarized them in one scoring
system. As a result, the ST elevation score exhibited signiﬁcant
differences among the 3 types of ST elevation in patients
with Brugada-type ECG patterns. This scoring system is unique
and may be useful to quantify the ‘‘severity’’ of ST elevation
in patients with Brugada-type ECG patterns, which is visually
evaluated. Additionally, we have shown the usefulness of the ST
elevation score for predicting future risk by hypothesizing that
patients showing more prominent ST elevations, especially coved-
shaped patterns and high ST elevations in a larger area, would be
at higher risk. The result was that the ST elevation score was
signiﬁcantly higher in patients with family history risk factors or
inducible VF in the EPS than in those without. More importantly,
the score was also higher in patients with new-onset VF than in
those without, although the number of event cases was severely
limited. These results indicate the possibility of applying this
scoring system as a useful index for the risk stratiﬁcation of
asymptomatic Brugada-type ECG cases.
In our study, 3/95 patients (3.2%) of primary VF prevention had
spontaneous VF episodes during the 63735 months observation
period, which is a relatively higher incidence than that in other
reports [29,30]. The reason for this difference is unclear, but it
may be inﬂuenced by the observation period. Interestingly, the
3 patients had the VF episodes after 5 years of follow-up, which
are relatively long observation periods [29,30]. Although the
number of patients is limited, the ﬁndings from our observation
might indicate that spontaneous VF episodes may appear after a
relatively longer observation time. Additionally, the 3 patients
exhibited a few common features, such as family history of risk
factors and VF induction. These are risk factors for VF that have
been emphasized in other studies [30]; however, high ST-eleva-
tion scores might be an additional risk factor for predicting VF in
S. Ishikawa et al. / Journal of Arrhythmia 28 (2012) 207–213212patients with primary prevention, because patients 1 and
2 showed markedly high ST-elevation scores. However, patient
3 showed a relatively low ST-elevation score, which although was
not very low but appeared to be similar to the mean values found
in patients without spontaneous VF. On the basis of these results,
the ST elevation score may be considered as one of the risk factors
for predicting VF in cases with Brugada-type ECG pattern. Because
VF may also occur in patients without spontaneous VF episodes,
the role of these risk factors, including ST-elevation score, should
be evaluated in larger populations and through longer observa-
tion periods in future studies.
4.3. Limitations
Our present and unique study has a few limitations. First, the
number of patients, especially the number of event cases, was
limited. Second, the evaluation of ST elevations was limited, in
that we considered only daytime ECG recordings. Because the ST
elevation in Brugada syndrome is exaggerated by vagal stimula-
tion, evaluation at night should be included, if possible. Third,
because this was a retrospective analysis with limited number of
patients with Brugada-type ECG pattern, we could not indicate
the risk factors in multivariable analysis. Finally, the weightings
in the scoring system should be evaluated. Here, we allocated the
coved score twice the weighting as that for the saddleback score.
This balance was set in accordance with the relative risk of coved-
type vs. saddleback-type ST elevations described in previous
studies [11], and also to distinguish the types 1–3 ECG patterns
that were determined using standard 12-lead ECG recordings in
accordance with the consensus report [4,5]; however, optimal
weighting should be determined by examining a larger number of
patients.5. Conclusions
We propose the use of the ST elevation score in multi-ECG
traces by using VP-ECG system in patients with Brugada-type ECG
patterns. The scores obtained enabled proper distinction of ST
elevation types in 1–3 ECG patterns, and the scores were high
in patients with a history of risk factors or new-onset VF
among asymptomatic Brugada patients. Thus, the ST-elevation
score might become a unique and useful index for risk stratiﬁca-
tion in patients with Brugada-type ECG patterns.Conﬂict of interest
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